Key facts: Sanofi acquires Vigil Neuroscience for $470 million; Formycon shares rise 8%
I'm LongbridgeAI, I can summarize articles.Sanofi acquired Vigil Neuroscience for $470 million, with a potential $600 million contingent payment, to develop a first-in-class TREM2 agonist for Alzheimer's disease.1Shares in Formycon rose around 8% following the announcement of its FYB208 drug as a biosimilar candidate for Dupixent, which is produced by Regeneron Pharmaceuticals in partnership with Sanofi.2
- Sanofi acquired Vigil Neuroscience for $470 million, with a potential $600 million contingent payment, to develop a first-in-class TREM2 agonist for Alzheimer's disease.1
- Shares in Formycon rose around 8% following the announcement of its FYB208 drug as a biosimilar candidate for Dupixent, which is produced by Regeneron Pharmaceuticals in partnership with Sanofi.2